News

October 18, 2021 Ipsen adds another program into its pre-clinical R&D Oncology pipeline through an exclusive worldwide collaboration with Accent Therapeutics, targeting the RNA modifying protein, METTL3
September 28, 2020 Fierce Biotech names Accent Therapeutics as one of its “Fierce 15” Biotech Companies of 2020
September 25, 2020 Accent Therapeutics Appoints Oncology Drug Development Veteran Julie Hambleton to its Board of Directors
June 4, 2020 Accent Therapeutics and AstraZeneca to Discover and Develop Novel Cancer Therapeutics in New Collaboration
April 23, 2020 Accent Therapeutics Announces $63 Million Series B Financing to Advance Novel, Precision Cancer Therapies Targeting RNA-Modifying Proteins
October 28, 2019 Accent Presents "Elevated Cancer-Intrinsic Type I Interferon Signaling Confers a Dependency on the RNA Editor ADAR1" (AACR-NCI-EORTC 2019)
October 27, 2019 Accent Presents "METTL3/14 is a Validated, Druggable Therapeutic Target for AML" (AACR-NCI-EORTC 2019)
September 3, 2019 Accent Therapeutics Appoints Shakti Narayan as Chief Executive Officer
March 27, 2019 Accent Presents "Elevated Cancer-Intrinsic Type I Interferon Signaling Confers a Dependency on the RNA Editor ADAR1" (GRC 2019)
March 25, 2019 Accent Presents "A Mass Spectrometric Assay for METTL3/14 Methyltransferase Activity" (GRC 2019)
February 4, 2019 Accent Presents "Elevated Cancer-Intrinsic Type I Interferon Signaling Confers a Dependency on the RNA Editor ADAR1" (Keystone 2019)
January 4, 2019 Catch our President & CSO, Robert Copeland, discussing RNA-modifying proteins on C&EN's podcast, Stereo Chemistry
October 1, 2018 Download a new poster from Nature Structural & Molecular Biology on epitranscriptome regulation, a key mechanism affecting gene expression as well as cellular functions, development and disease. 
May 18, 2018 Accent Therapeutics Announces Company Launch with $40 Million Series A Financing for Novel, Precision Cancer Treatments Targeting RNA-Modifying Proteins